Search PubMed⌕ Search

Biomedical subjects

P L Ilbery

Publications and source records attributed to P L Ilbery.

At least 19 recordsLinked to original sources
PubMed1984

Licensing.

Explore the source record for details and available documents.

Australia↗
PubMed1983

The use of levamisole as an adjunct to chemotherapy and radiotherapy in the treatment of small cell carcinoma of the lung.

To test the efficacy of immunotherapy in the treatment of small cell carcinoma of the lung, patients were allocated at random, in a double-blind controlled trial, to treatment with either levamisole or placebo as an adjunct to chemotherapy with multiple drugs (cyclophosphamide, vincristine, methotrexate and adriamycin) and to radiotherapy. We report here the results of a pilot study of 13 patients. The median survival period of the patients who were given levamisole was 25 weeks. This was significantly shorter (P less than 0.05) than that of the patients who were given placebo (46 weeks).

Adult↗
PubMed1979

Mammography--use or abuse.

Excluding the question of cost, at the present time the benefit of mammography associated with physical examination over the age of 50 appears proven as an intervention measure. With recent advances in radiological techniques, women under 50 appear to be advantaged by the performance of mammography but the benefit through the use of screening has yet to be proven by clinical trial. Screening might be restricted to the high risk group of patients with previous or present breast disorders and a family history of breast cancer in close relatives. Promotion of BSE and screening needs continuing education of the public, particularly concerning the value of early detection to successful treatment, and requires agreement on the methods and indications for screening (and subsequent treatment) by those advocating the programmes in order to keep the public's confidence. Overenthusiasm and polarity of views are to be avoided, so that health educators may be allowed to give the same message for credibility's sake.

Adult↗
PubMed1978

Cost of health care services in the treatment of cancer.

In the provision of cancer therapy, usage of expensive cancer facilities and deployment of cancer services to the full, the aims and performance of a comprehensive cancer centre have been discussed. Increasing utilization of cancer chemotherapy and its cost have been contrasted with that of radiotherapy. With the current expansion in oncology there is a limit to what the cancer centre can make available within the specific tumour clinic role and for general cancer treatment purposes at other hospitals. It is timely to attempt rationalization of the cancer arrangements peripheral to the centre.

Antineoplastic Agents↗
PubMed1975

General immune status in cancer therapy.

Theoretical considerations in immunotherapy, such as the timing of challenge, which could rank second to reduction of tumour volume in producing lasting regressions, are outlined and illustrate the need for tests to monitor immune status. Estimation of immunosuppression, in order to define cancer therapy schedules providing least interference with what might be useful host response to tumour, is described in terms of a reliable radioimmunoassay method assessing lymphocyte replicating ability (LRA). The extent of the effect of radiation or radiomimetic drugs in vitro can be shown upon LRA in response to phytohaemagglutinin or to irradiated cells. In clinical research LRA assessment makes a satisfactory test of the general immune state of patients undergoing cancer treatments, given that matched control subjects are available throughout the period of observation to allow repeated assessment of the relative response. An assured relative response seems feasible if all examinations are related to a common standard, the stored reference lymphocyte. Conversely a relative response can be measured against stored target cells.

Adjuvants, Immunologic↗